logo.jpg
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron)
December 02, 2021 04:30 ET | Helsinn Healthcare S.A.
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global...
logo.jpg
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea
July 31, 2018 04:00 ET | Helsinn Healthcare S.A.
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV is one of the most common and distressing side effects of cancer chemotherapyIncluded as a treatment option...
TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
October 25, 2017 19:15 ET | TESARO, Inc.
VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...
TESARO® logo_RGB_small.png
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
April 26, 2017 08:30 ET | TESARO, Inc.
VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...
TESARO® logo_RGB_small.png
TESARO Receives Positive CHMP Opinion for VARUBY®
February 27, 2017 02:00 ET | TESARO, Inc.
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...
TESARO® logo_RGB_small.png
TESARO Announces Five Abstracts to be Presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2016 17:30 ET | TESARO, Inc.
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016...
TESARO® logo_RGB_small.png
TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
March 23, 2016 09:00 ET | TESARO, Inc.
WALTHAM, Mass., March 23, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for...
TESARO® logo_RGB_small.png
TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
March 14, 2016 08:05 ET | TESARO, Inc.
WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA)...
Midatech Agrees to Acquire Marketed Oncology Product, Zuplenz®, From Galena Biopharma, Inc.
December 18, 2015 02:00 ET | Midatech Pharma PLC
OXFORDSHIRE, United Kingdom, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM:MTPH), the international specialty pharmaceutical company focused on developing and commercialising products in...
red.jpg
RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014
April 30, 2014 07:00 ET | RedHill Biopharma Ltd.
RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers In light of the positive results, and subject to regulatory...